Sydney, June 6, 2007 AEST (ABN Newswire) - Ventracor (ASX: VCR)(ADR: VTCRY) today announced the first patient implant in the US Bridge to Transplant (BTT) pivotal trial of the VentrAssist(tm) left ventricular assist device (LVAD) at the Medical University of Minnesota, in Minneapolis.
The Principal Investigators at the Medical University of Minnesota, Professor Lyle Joyce and Dr. Andrew Boyle and the rest of the LVAD team at Minnesota said, "We at the University of Minnesota are proud to take a leadership role in this important trial and are very pleased with the results obtained thus far with our VentrAssist patients."
Ventracor Chief Executive Officer Peter Crosby said: "As of today, there have been 120 patients implanted with the VentrAssist world wide who have collectively enjoyed approximately 55 patient years of support, with the longest duration support two years and eight months. The VentrAssist is the only third generation LVAD and the only centrifugal LVAD in clinical trials in the United States, and has the largest clinical experience of all third generation centrifugal devices."
Ventracor is sponsoring two major US trials to be conducted in approximately 350 patients at up to 40 clinical sites. Details of the trials were published in the March 2007 Investor Update and are available on the Company's website.
Mr. Crosby added: "We hope to complete patient enrolment in these two trials in approximately two years. This would put us well on the path towards achieving US regulatory approval with a leadership position to take advantage of a potentially huge world market."
Contact
Andrew Geddes
Manager, Investor Relations
Tel: 02 9406 3100
U.S. Media Contact:
Douglas MacDougall
MacDougall Biomedical Communications
Tel: 508-647-0209
| ||
|
